[Mitotic index and kinetics of lymphocyte proliferation in biologic monitoring].
Xenobiotics exposure generates concern, mostly because the effects on DNA and cancer generation are not well known. Identification of dangerous agents are difficult due to the large latency period between exposure and clinic manifestations (from years to several generations). Biomarkers are proposed for human biomonitoring of individuals that due to natural, occupational, medical or accidental exposure are considered of "high risk". The present work evaluates the use of biomarkers of cell proliferation in lymphocyte cultures of individuals exposed to hydro-arsenicism, dangerous industrial products (DIP), neuro-cysticercosis patients under treatment with praziquantel and individuals treated with metronidazole. The slowing of cell proliferation in arsenic exposed individuals and in neuro-cysticercosis patients, in which higher cancer frequencies han been reported, evidence the usefulness of these parameters. We did not find lymphocyte proliferation changes due to DIP exposure although we did find an increased proliferation due to metronidazole treatment. The biological meaning of these data opens new research interests.
Ostrosky Wegman
P
P
Instituto de Investigaciones Biomédicas, UNAM.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000980:Antiplatyhelmintic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000994:Antitrichomonal Agents / Q000009:adverse effects / Q000627:therapeutic use; D020261:Arsenic Poisoning; D015415:Biomarkers; D002455:Cell Division; D002478:Cells, Cultured; D002908:Chronic Disease; D003551:Cysticercosis / Q000175:diagnosis; D004784:Environmental Monitoring; D015386:Hazardous Substances / Q000009:adverse effects; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects*; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D008940:Mitotic Index; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use; D014881:Water Supply; D015262:Xenobiotics / Q000009:adverse effects
D000980:Antiplatyhelmintic Agents; D000994:Antitrichomonal Agents; D015415:Biomarkers; D015386:Hazardous Substances; D015262:Xenobiotics; D008795:Metronidazole; D011223:Praziquantel